Key facts
- Bactolife’s last known valuation is $66.5M (Aug 2023).
- It has raised $79.1M; the latest was Later Stage VC ($35.0M) in Jan 2026.
- Notable investors include Gates Foundation, InnoFounder, Novo Holdings, Denmark's Export and Investment Fund, Selfinvest — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Bactolife
- ·The full record, as it builds
Funding rounds
No funding rounds for Bactolife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bactolife
Developer of proprietary binding protein ingredients designed to fortify the gut microbiome and reduce the risk of gastrointestinal infections in humans and animals. The company's platform focuses on neutralizing harmful pathogens and their toxins while preserving beneficial microbes, it aims to empower worldwide gut health and reduce dependence on antimicrobials to combat antimicrobial resistance, improving human and animal health through their innovative gut microbiome modulation technologies.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2017
- Employees
- 51
- Website
- bactolife.com/
- Ownership
- Privately Held (backing)
Bactolife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bactolife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bactolife in its N-PORT filings yet. We sweep new filings monthly.